Rapt Therapeutics, INC
Market Movers (8-K)
RAPT Therapeutics, Inc. has completed its merger with GlaxoSmithKline LLC's subsidiary, Redrose Acquisition Co., becoming a wholly-owned entity.
GSK announced a definitive agreement to acquire RAPT Therapeutics for $58.00 per share in cash, valuing the company at approximately $2.2 billion, to gain its lead asset ozureprubart for food allergies.
Better than expected
RAPT Therapeutics presented positive Phase 2 data for ozureprubart in Chronic Spontaneous Urticaria and outlined plans for pivotal trials and a Phase 2b food allergy study, projecting a cash runway into mid-2028.
Capital raise
Better than expected
RAPT Therapeutics announces the mutual agreement for Dr. William Ho, Chief Medical Officer, to depart on December 31, 2025, and transition into a strategic consulting role.
RAPT Therapeutics announced its third quarter 2025 financial results, highlighted by positive Phase 2 CSU data, initiation of a Phase 2b food allergy trial, and a $250 million public offering.
Better than expected
Capital raise
RAPT Therapeutics, Inc. announced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share, aiming to raise approximately $234.4 million in net proceeds.
Capital raise
Quarterly Earnings (10-Q)
RAPT Therapeutics reported Q3 2025 results, highlighting positive Phase 2 data for ozureprubart in CSU and a successful $234.4 million public offering to fund ongoing clinical development.
Capital raise
Better than expected
RAPT Therapeutics reported a reduced net loss in Q2 2025, driven by lower R&D expenses following the termination of its zelnecirnon program, while continuing development of RPT904 and tivumecirnon.
Delay expected
Worse than expected
Capital raise
10-Q: RAPT Therapeutics Reports Q1 2025 Financial Results, Highlights RPT904 and Tivumecirnon Development
RAPT Therapeutics reports a net loss of $17.2 million for Q1 2025, focusing on advancing RPT904 and tivumecirnon while managing cash resources.
Worse than expected
Capital raise
RAPT Therapeutics reports a net loss of $18.4 million for the third quarter of 2024, alongside strategic program adjustments and a workforce reduction.
Worse than expected
Delay expected
Capital raise
RAPT Therapeutics' Q2 2024 results reveal a net loss of $58.2 million, alongside clinical trial holds and a significant workforce reduction.
Worse than expected
Delay expected
Capital raise
RAPT Therapeutics reported its first quarter 2024 financial results, which included a net loss of $30.5 million, while also addressing clinical holds on key drug trials.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
RAPT Therapeutics details its 2024 financial performance and outlines key developments in its clinical-stage immunology-based biopharmaceutical programs.
Worse than expected
RAPT Therapeutics, a clinical-stage biopharmaceutical company, released its 2023 financial results and provided updates on its clinical development programs, including a recent clinical hold on its zelnecirnon trials.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline LLC for $58.00 per share in cash, completing a tender offer and subsequent merger.
RAPT Therapeutics director Mary Ann Gray reports the disposition of common stock and stock options following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics Director Michael F. Giordano reports the disposition of all common stock, RSUs, and stock options following the acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics, Inc. director Ashley L. Dombkowski reports changes in beneficial ownership following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.
RAPT Therapeutics' Chief Financial Officer, Rodney Young, reported the disposition of common stock and conversion of stock options following the company's acquisition by GlaxoSmithKline for $58.00 per share.
RAPT Therapeutics Chief Scientific Officer Dirk G. Brockstedt disposed of common stock and stock options following the company's acquisition by GlaxoSmithKline LLC for $58.00 per share.
Proxy Statements (Def-14A)
RAPT Therapeutics will hold its annual meeting on May 29, 2025, with proposals including the election of a director, ratification of the auditor, executive compensation, and a potential reverse stock split.
RAPT Therapeutics is asking stockholders to approve a reverse stock split, a new equity incentive plan, and an amendment to its employee stock purchase plan at the upcoming annual meeting.
Capital raise
DEFA14A: RAPT Therapeutics Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
RAPT Therapeutics, Inc. announces its 2024 Annual Meeting and provides details on proposals for stockholder voting, including the election of directors and ratification of the company's independent auditor.
RAPT Therapeutics is holding its annual stockholder meeting on May 22, 2024, to elect directors and ratify the appointment of its independent auditor.
Schedule 13G - Passive Investments
OrbiMed Advisors LLC has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership stake in RAPT Therapeutics, Inc.
RTW Investments, LP and Roderick Wong have filed a Schedule 13G, reporting no beneficial ownership of RAPT Therapeutics, Inc. common stock as of March 31, 2026.
RTW Investments, LP and Roderick Wong, M.D. have reported a 5.9% beneficial ownership stake in RAPT Therapeutics, Inc. common stock.
Deep Track Capital and affiliates report a 0.40% beneficial ownership in RAPT Therapeutics, Inc. common stock as of December 31, 2025.
Glazer Capital, LLC and Paul J. Glazer have reported a 5.36% beneficial ownership stake in RAPT Therapeutics, Inc. common stock.
OrbiMed Advisors LLC has reported a 6.6% beneficial ownership stake in RAPT Therapeutics, Inc., holding 1,086,618 shares of common stock.